To order this 750+ page report, please visit this link
Key Inclusions
§ A detailed review ofthe overall landscape of the biopharmaceutical contract manufacturing market, featuring acomprehensive list of active CMOs and detailed analysis of the manufacturingservice providers based on a number of parameters, such as scale of operation(preclinical, clinical and commercial), type of biologics manufactured(peptides / proteins, antibodies, vaccines, cell therapies, gene therapies,antibody drug conjugates, vectors, biosimilars, nucleic acids and others), typeof expression systems used (mammalian, microbial and others), year ofestablishment, employee size, geographical location of the CMO, number ofmanufacturing facilities, as well as the location of these facilities, GMPcompliance, affiliations to regulatory agencies, type of bioreactors used(single-use bioreactors and stainless steel bioreactors), mode of operation ofbioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
§ Elaborate profiles of key players that have adiverse range of capabilities for the development, manufacturing and packagingof biologics. Each profile provides an overview of the company, its financialperformance (if available), information related to its service portfolio,manufacturing facilities, and details on partnerships, recent developments(expansions), as well as a comprehensive future outlook.
§ A detailed discussion on the key enablers inthis domain, including certain niche product classes, such as antibody drugconjugates (ADCs), bispecific antibodies, cell therapies, gene therapies andviral vectors, which are likely to have a significant impact on the growth ofthe contract services market.
§ A case study on the growing global biosimilarsmarket, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
§ A case study comparing the key characteristicsof large molecule and small molecule drugs, along with details on the varioussteps involved in their respective manufacturing processes.
§ A discussion on challenges related to in-housemanufacturing, featuring a brief overview of the various parameters that a drug/ therapy developer may need to take into consideration while deciding whetherto manufacture its products in-house or outsource.
§ An analysis of the recent collaborations(signed since 2013) focused on the contract manufacturing of biologics; theanalysis is based on various parameters, such as the year in which theagreement was signed, type of agreement, focus area and type of biologics.
§ A detailed analysis of the various mergers andacquisitions that have taken place in this domain, highlighting the trend inthe number of companies acquired between 2013-2018, along with the geographicaldistribution of this activity. The analysis also depicts the relationshipbetween important deal multiples based on the revenue, number of employees andexperience of the acquired company.
§ An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlightingvarious facility and capability expansions. In addition, it provides informationon the technology advancements related to biomanufacturing.
§ A detailed capacity analysis, taking intoconsideration the individual development and manufacturing capacities ofvarious stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs)in the market, using data from both secondary and primary research. The studyexamines the distribution of global biopharmaceutical manufacturing capacity by scale of operation(preclinical / clinical, commercial), size of company (small-sized, mid-sized,large and very large), and geography (North America (the US and Canada), Europe(Italy, Germany, France, Spain, the UK and rest of Europe), Asia and MiddleEast (China, India, Japan, South Korea and rest of the Asia and Middle East),and rest of the world (including Australia).
§ An informed estimate of the annual demand forbiologics, taking into account the top 20 biologics, based on a variousrelevant parameter, such as target patient population, dosing frequency anddose strength of the abovementioned products.
§ A discussion on affiliated trends, key driversand challenges, under a comprehensive SWOT framework, which are likely toimpact the industry’s evolution, including a Harvey ball analysis, highlightingthe relative effect of each SWOT parameter on the overall pharmaceuticalindustry.
§ A survey analysisfeaturing inputs solicited from various experts who are directly / indirectlyinvolved in providing CMO services to medical device developers.
To request for Sample Report – https://www.rootsanalysis.com/reports/250/request-sample.html
The report also features the likelydistribution of the current and forecasted opportunity across important marketsegments, mentioned below:
§ CommonlyOutsourced Business Operations
§ ActivePharmaceutical Ingredients (API)
§ FinishedDosage Formulations (FDF)
§ Typesof Expression System
§ Mammalian
§ Microbial
§ Others
§ CompanySize
§ Small
§ Mid-Sized
§ Largeand Very Large
§ Scaleof Operation
§ Preclinical
§ Clinical
§ Commercial
§ KeyGeographical Region
§ NorthAmerica
§ Europe
§ Asia-Pacific
§
§ To requestfor Customize Report – https://www.rootsanalysis.com/reports//request-customization.html1
Key Questions Answered
§ Who are the key manufacturers (industry / non-industry) ofcell-based therapies, across the world?
§ Whatis the global demand for biologics-based therapies?
§ Whatare the major recent developments (such as partnerships and expansions) in thisindustry?
§ Whatkind of partnership models are commonly adopted by stakeholders in this domain?
§ What is the current, installed contract manufacturingcapacity for biologics?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
Youmay also be interested in the following titles:
1. CellTherapy Manufacturing Market (3rd Edition), 2019-2030
2. AntibodyContract Manufacturing Market, 2020-2030
3. China Biopharmaceutical ContractManufacturing Market, 2020-2030
4. PeptideTherapeutics: Contract API Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
Contact Information
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
